Clover Health CLOV: Chief Legal Officer Karen Soares Executes Planned Sale of 51,700 Shares

Pre-Arranged Trading Plan Facilitates Officer Share Sale

Karen Soares, Chief Legal Officer of Clover Health Investments Corp., completed the sale of 51,700 Class A Common Stock shares on July 20, 2026, as disclosed in the company’s filing. The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, which allows insiders to execute predetermined trading schedules while complying with regulatory safe harbor provisions to avoid insider trading allegations.

The shares were sold through multiple transactions at prices ranging from $4.46 to $4.59 per share. The weighted average price was $4.51, indicating the sales occurred in tranches rather than a single block. Clover Health committed to providing detailed breakdowns of shares sold at each price point upon request by investors, regulators, or the SEC.

Beneficial Ownership Remains Significant After Sale

Following the divestment of 51,700 shares, Karen Soares continues to hold beneficial ownership of 1,505,522 shares of Clover Health Class A Common Stock. This substantial holding underscores her ongoing investment and alignment with the company’s performance. The shares are held directly by Soares, not through intermediaries.

Such significant insider ownership typically aligns management interests with shareholders, fostering confidence in company governance. Disclosure of these holdings complies with Section 16 of the Securities Exchange Act of 1934, promoting transparency for investors.

Rule 10b5-1 Plan Ensures Compliance with Insider Trading Regulations

The sale was executed under a Rule 10b5-1 trading plan, a formal mechanism enabling insiders to set predetermined trading schedules. Under Rule 10b5-1(c), plans must be entered in good faith without possession of material nonpublic information at adoption. Soares adopted her plan on March 13, 2026, roughly four months prior to the sale, adhering to regulatory requirements and preventing trade timing based on confidential information.

This advance planning aligns with standard practices for public company insiders under SEC oversight. The filing’s disclosure of the sale’s execution under this plan provides investors with clarity on the transaction’s nature and timing.

Chief Legal Officer Role and Reporting Responsibilities

Karen Soares holds the position of Chief Legal Officer at Clover Health Investments Corp., overseeing legal affairs, regulatory compliance, contracts, litigation, and legal strategy. As an officer, she is obligated under Section 16 of the Securities Exchange Act of 1934 to report changes in beneficial ownership within two business days, a requirement met with this filing.

Her status as an officer combined with a sizable shareholding places her transactions under close scrutiny by investors and regulators. The filing was signed by attorney-in-fact Peter J. Rivas, reflecting common legal representation practices in insider transaction reporting.

Transaction and Filing Dates Confirm Timely Disclosure

The transaction occurred on July 20, 2026, the same date as the filing, demonstrating prompt compliance with SEC rules requiring Form 4 submissions within two business days of insider transactions. This timely disclosure ensures investors receive near-immediate access to insider trading information for informed decision-making.

Share Sale Pricing and Market Execution

The shares sold ranged in price from $4.46 to $4.59, with a weighted average of $4.51. This narrow 2.9% price range suggests sales occurred during a period of relative stock price stability or through execution strategies minimizing market impact. Multiple transactions at varying prices indicate a methodical divestment approach rather than a single bulk sale.

While the filing does not specify exact transaction dates or share counts per price point, Clover Health’s commitment to provide such details upon request supports transparency. The price range offers investors insight into the valuation level at which the officer divested shares.

Clover Health’s Governance and Disclosure Practices

Clover Health Investments Corp., incorporated in Delaware with headquarters in Wilmington, Delaware, maintains a governance framework including officers like Soares whose insider transactions are subject to stringent reporting requirements. Delaware incorporation provides a robust legal foundation for corporate governance and shareholder protections.

The company’s adherence to SEC disclosure regulations, exemplified by this insider transaction report, contributes to investor transparency and market integrity. Regular reporting of insider trades enables market participants to monitor insider equity changes and assess management’s confidence in company prospects.

Investor Insights from Insider Trading Activity

Insider trading disclosures such as this provide valuable data points for investors evaluating Clover Health. Although a single officer sale does not inherently indicate company outlook, patterns of insider buying or selling across multiple executives can signal management sentiment. Soares’ use of a pre-established trading plan indicates the sale followed a predetermined schedule, not reactive trading based on current company developments.

Investors should consider cumulative insider trading trends alongside operational and financial performance to form comprehensive evaluations. Rule 10b5-1 plans enable insiders to trade systematically without influence from short-term market or informational advantages, distinguishing such sales from opportunistic insider transactions.

Regulatory Filing Compliance and Legal Framework

This disclosure, filed as a Statement of Changes in Beneficial Ownership under Section 16(a) of the Securities Exchange Act of 1934, includes standard legal language regarding penalties for false statements under federal law. This framework ensures accuracy and timeliness in insider transaction reporting.

The filing identifies Clover Health Investments Corp. /DE as the issuer with NASDAQ ticker CLOV. It does not include additional corporate or financial updates, consistent with the limited scope of insider trading disclosures. Investors seeking broader company information should reference other public filings and announcements from Clover Health.